Table 2 Cox regression analysis for all LUAD patients
From: Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients
Covariates | A. K-Ras4A expression | Covariates | B. K-Ras4A proportion | ||||||
|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
HRa (95% CIb) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Age (≥65 years) | 1.154 (0.857−1.553) | 0.346 | 1.198 (0.879−1.632) | 0.253 | Age (≥65 years) | 1.154 (0.857−1.553) | 0.346 | 1.206 (0.885−1.643) | 0.236 |
Gender (Male) | 1.063 (0.797−1.417) | 0.678 | 1.190 (0.871−1.625) | 0.274 | Gender (Male) | 1.063 (0.797−1.417) | 0.678 | 1.185 (0.867−1.619) | 0.287 |
Smoking history | 1.019 (0.887−1.170) | 0.790 | 1.038 (0.895−1.202) | 0.625 | Smoking history | 1.019 (0.887−1.170) | 0.790 | 1.039 (0.896−1.204) | 0.615 |
K-Ras4A expression (low) | 0.766 (0.573−1.023) | 0.0705 | 0.900 (0.644−1.257) | 0.537 | K-Ras4A proportion (low) | 0.952 (0.714−1.268) | 0.735 | 1.049 (0.762−1.444) | 0.770 |
KRAS amplification (Not amplified) | 0.580 (0.382−0.880) | 0.0104 | 0.623 (0.395−0.983) | 0.0421 | KRAS amplification (Not amplified) | 0.580 (0.382−0.880) | 0.0104 | 0.619 (0.393−0.977) | 0.0393 |
KRAS mutations (Present) | 1.194 (0.867−1.643) | 0.277 | 1.246 (0.856−1.813) | 0.252 | KRAS mutations (Present) | 1.194 (0.867−1.643) | 0.277 | 1.319 (0.915−1.901) | 0.138 |
EGFR mutations (Present) | 1.322 (0.831−2.104) | 0.239 | 1.460 (0.869−2.454) | 0.153 | EGFR mutations (Present) | 1.322 (0.831−2.104) | 0.239 | 1.436 (0.855−2.412) | 0.172 |
Pathological stage (III/IV) | 2.635 (1.939−3.581) | 5.94E-10 | 2.486 (1.796−3.443) | 4.14E-8 | Pathological stage (III/IV) | 2.635 (1.939−3.581) | 5.94E-10 | 2.513 (1.815−3.480) | 2.90E-8 |